RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Clinical trials for RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test powerful new Immune-Boosting cocktail against tough ovarian cancers
Disease control Recruiting nowThis study is testing whether adding a new immune-stimulating drug (CDX-1140) to two existing cancer drugs works better for women whose ovarian cancer has returned. The goal is to see if this three-drug combination can shrink tumors more effectively, help patients live longer, an…
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Scientists test new drug duo to target Tough-to-Treat gynecologic cancers
Disease control Recruiting nowThis early-stage study is testing a new combination of two oral drugs, M1774 and ZEN-3694, for women with recurrent ovarian or endometrial cancer. The main goals are to find the safest and most effective dose and to see how well the drugs work together to stop cancer cell growth.…
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC